It has been further demonstrated that EZH2 controls melanoma escaping mechanisms during T cell-targeting immunotherapies (Zingg et al., 2017) and because the upregulation of EZH2 and its histone modification H3K27me3 seems correlated to melanoma progression and resistance to immune checkpoint blockade, clinical trials based on EZH2 inhibitors are strongly suggested (Hoffmann et al., 2020). Here, EZH2 is linked to melanoma.